X4 Pharmaceuticals (XFOR) Tops Q2 EPS by 46c

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q2 EPS of $0.45, $0.46 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $260 thousand versus the consensus estimate of $15.27 million.

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.

You May Also Be Interested In

• Trump Did Not Repeat Termination Of Interim Deal With Iran During Nato Summit, Source Familiar With The Talks Says - Reuters
• Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
• SEALSQ and GlobalFoundries sign MoU on post-quantum cryptography chips